Aurealis Pharma company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Series B | Alive

Total Raised


Last Raised

$7.75M | 3 yrs ago

About Aurealis Pharma

Aurealis Pharma is a biopharmaceutical company focusing on developing broadly applicable proprietary technology to re-educate the distorted host immune microenvironment in chronic inflammation and cancer to its proper state. Company's technology is based on safe food-grade lactic acid bacteria delivering multiple human therapeutic proteins in target tissue effectively, safely and economically to address the unmet medical need in chronic wounds and cancer.

Aurealis Pharma Headquarter Location

Hochbergerstrasse 60C

Basel, CH-4057,


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Aurealis Pharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Aurealis Pharma is included in 2 Expert Collections, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Latest Aurealis Pharma News

Aurealis Pharma Announces CHF7.8 Million Financing Round

Feb 12, 2019

Aurealis Pharma develops novel three-in-one combination biologics for chronic non-healing wounds and cancer. The funds will be used to advance the chronic wound lead candidate AUP-16 to diabetic foot ulcer patients under new brand Aurealis Therapeutics AG. The Basel, Switzerland and Kuopio, Finland based privately-held biopharmaceutical company Aurealis Pharma announced 7.8MCHF funding provided by Swiss and foreign private investors, Finnvera plc, and Business Finland – the Finnish Innovation Funding Agency. The Company also confirmed the de-merger and a plan to develop and commercialize the AUP-16 under a new legal entity – Aurealis Therapeutics AG. The proceeds of this financing will be used in Aurealis Therapeutics AG to fund the AUP-16 first-in-human Phase 1 clinical study for diabetic foot ulcers (DFU). AUP-16 first-in-human Phase 1 clinical study for diabetic foot ulcers (DFU) clinical trial application (CTA) was submitted in Q4/2018 to the German Health Authority Paul-Ehrlich-Institute. CTA approval is expected during Q1/2019 and the first patient is planned to be treated in Q2/2019. The new separate business unit Aurealis Therapeutics is entirely dedicated to the "development and commercialization of the product AUP-16". These activities will be separated from the other parallel development activities within Aurealis Pharma AG including oncology, which will remain with it. All relevant assets of the product AUP-16 and all the associated obligations will be transferred to Aurealis Therapeutics AG. It is emphasized that the de-merger has no effect on the Board of Directors, management team and staff. They all remain at Aurealis Therapeutics and its subsidiary Aurealis Oy. Furthermore, the de-merger has no effect on the ongoing AUP-16 collaborations, contracts and obligations. “Aurealis Therapeutics AG is funded until diabetic foot ulcer phase 1 results and can now focus on maximizing the AUP-16 clinical development. Aurealis Pharma AG, on the other hand, will focus on oncology with its renewed strategy and plan.” said Dr. Juha Yrjänheikki, CEO of Aurealis Therapeutics AG. (Press release)

Aurealis Pharma Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Aurealis Pharma Rank

  • Where is Aurealis Pharma's headquarters?

    Aurealis Pharma's headquarters is located at Hochbergerstrasse 60C, Basel.

  • What is Aurealis Pharma's latest funding round?

    Aurealis Pharma's latest funding round is Series B.

  • How much did Aurealis Pharma raise?

    Aurealis Pharma raised a total of $13.65M.

  • Who are the investors of Aurealis Pharma?

    Investors of Aurealis Pharma include Finnvera, Business Finland Venture Capital and Tekes.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.